POST-POLYCYTHEMIA VERA MYELOFIBROSIS

This early-phase study tests whether the drug tasquinimod, given alone or with ruxolitinib, can help control myelofibrosis (a type of bone marrow cancer). About 33 adults with primary or post-PV/ET myelofibrosis who cannot take or have stopped responding to standard JAK inhibitor…

This early-phase study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutatio…

This early-phase study tests an experimental oral medication, AJ1-11095, in about 76 adults with myelofibrosis (a rare bone marrow disorder) whose disease has not responded or has returned after treatment with a standard JAK2 inhibitor. The main goals are to check the drug's safe…

This study is for people who have already been taking the drug bomedemstat for certain blood cancers (like essential thrombocythemia or myelofibrosis) and are tolerating it well. The goal is to collect long-term safety information and see how well the drug continues to work. Abou…

This study is not testing a new treatment. Instead, it will follow about 200 people in Germany who have myelofibrosis (a bone marrow disorder) and anemia (low red blood cells). Researchers will record which treatments doctors choose, how the disease changes, and how patients feel…

This study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease …